YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α

Cancer Immunology, Immunotherapy

Volumn 62, Issue 3, 2013, Pages 517-527

  Takeuchi, Ario ^a   Shiota, Masaki ^a   Tatsugami, Katsunori ^a   Yokomizo, Akira ^a   Kuroiwa, Kentaro ^a   Dejima, Takashi ^a   Tanaka, Shingo ^a   Itsumi, Momoe ^a   Eto, Masatoshi ^b   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Immunotherapy; Interferon ; Renal cancer; STAT3; YB 1

Indexed keywords

ALPHA INTERFERON; STAT3 PROTEIN; Y BOX BINDING PROTEIN 1; YBX1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BRAIN DEVELOPMENT; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN POLYMORPHISM; T LYMPHOCYTE; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; GENE SILENCING; GENETICS; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, RENAL CELL; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEOLYSIS; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; Y-BOX-BINDING PROTEIN 1;

MLCS; MLOWN;

EID: 84877134575     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1356-8     Document Type: Article

References (46)

1. Mancuso A, Sternberg CN (2005) New treatments for metastatic kidney cancer. Can J Urol 12(Suppl 1):66-70; discussion 105. Review
2. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA (2005) Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 1496-14501
3. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865-875 (Pubitemid 26304070)
4. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Tomita Y (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1,463 patients. Eur Urol 57:317-325
5. Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T, Toma H, Nakazawa H, Hirao Y, Uemura H, Kagawa S, Kanayama H, Nose Y, Kinukawa N, Nakamura T, Jinnai N, Seki T, Takamatsu M, Masui Y, Naito S, Ogawa O (2007) STAT3 polymorphism predicts interferon-alpha response in patients with metastatic renal cell carcinoma. J Clin Oncol 25:2785-2791 (Pubitemid 47123187)
6. Darnell JE Jr (1997) STATs and gene regulation. Science 277:1630-1635 (Pubitemid 27446219)
7. Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis. Oncogene 19:2474-2488 (Pubitemid 30339203)
8. Takeda K, Akira S (2000) STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11:199-207 (Pubitemid 30337459)
9. Yu H, Jove R (2004) The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4:97-105 (Pubitemid 38198738)
10. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr (1999) Stat3 as an oncogene. Cell 98:295-303 (Pubitemid 29380565)
11. Darnell JE (2005) Validating Stat3 in cancer therapy. Nat Med 11:595-596 (Pubitemid 40868294)
12. Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109:1139-1142 (Pubitemid 34496590)
13. Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, Kano A, Iwamoto Y, Li E, Craft JE, Bothwell AL, Fikrig E, Koni PA, Flavell RA, Fu XY (2003) STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci USA 100:1879-1884 (Pubitemid 36254542)
14. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, Akira S (1999) Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39-49 (Pubitemid 29077382)
15. Alonzi T, Newton IP, Bryce PJ, Di Carlo E, Lattanzio G, Tripodi M, Musiani P, Poli V (2004) Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine 26:45-56 (Pubitemid 38410883)
16. Tatsugami K, Eto M, Naito S (2010) Influence of immunotherapy with interferon-alpha on regulatory T cells in renal cell carcinoma patients. J Interferon Cytokine Res 30:43-48
17. Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caraco C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N (2010) Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 8:76
18. Schwandt A, Garcia JA, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, Zhou M, Dreicer R, Rini BI (2011) Clinical and Immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 Tumor Immunostaining. J Clin Immunol 31(4):690-698
19. Uchiumi T, Fotovati A, Sasaguri T, Shibahara K, Shimada T, Fukuda T, Nakamura T, Izumi H, Tsuzuki T, Kuwano M, Kohno K (2006) YB-1 is important for an early stage embryonic development: neural tube formation and cell proliferation. J Biol Chem 281:40440-40449 (Pubitemid 46041847)
20. Lu ZH, Books JT, Ley TJ (2005) YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol 25:4625-4637 (Pubitemid 40705766)
21. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M (2003) The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays 25:691-698 (Pubitemid 36850797)
22. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, Kohno K (2004) The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 3:1485-1492 (Pubitemid 39562593)
23. Lee C, Dhillon J, Wang MY, Gao Y, Hu K, Park E, Astanehe A, Hung MC, Eirew P, Eaves CJ, Dunn SE (2008) Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 68:8661-8666
24. Takeuchi A, Eto M, Tatsugami K, Yamada H, Oki T, Kiyoshima K, Yoshikai Y, Naito S (2010) Mechanism of synergistic antitumor effect of sorafenib and interferon-alpha on treatment of renal cell carcinoma. J Urol 184:2549-2556
25. Naito S, Kotoh S, Goto K, Koga H, Hasegawa S, Noma H, Yamasaki T, Kumazawa J (1996) Establishment of two human renal cell carcinoma cell lines with different chemosensitivity. Hum Cell 9:101-108
26. Naito S, Kanamori T, Hisano S, Tanaka K, Momose S, Kamata N (1982) Human renal cell carcinoma: establishment and characterization of two new cell lines. J Urol 128:1117-1121 (Pubitemid 13211686)
27. Naito S, von Eschenbach AC, Fidler IJ (1987) Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice. J Natl Cancer Inst 78:377-385 (Pubitemid 17027755)
28. Gohji K, Fidler IJ, Tsan R, Radinsky R, von Eschenbach AC, Tsuruo T, Nakajima M (1994) Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer 58:380-384 (Pubitemid 24254648)
29. Shiota M, Yokomizo A, Kashiwagi E, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N, Naito S (2010) Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer Sci 101:1177-1185
30. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T, Naito S (2010) Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29:237-250
31. Takeuchi A, Eto M, Yamada H, Tatsugami K, Naito S, Yoshikai Y (2012) A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice. Int J Cancer 130(2):365-376. doi: 10.1002/ijc.26009
32. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M (2002) Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168:762-765 (Pubitemid 34793359)
33. Kortylewski M, Yu H (2007) Stat3 as a potential target for cancer immunotherapy. J Immunother 30:131-139 (Pubitemid 46667794)
34. Kreil S, Waghorn K, Ernst T, Chase A, White H, Hehlmann R, Reiter A, Hochhaus A, Cross NC (2010) A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon alpha. Haematologica 95:148-152
35. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC (2004) YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59:337-349 (Pubitemid 38509767)
36. Wright JJ (2010) Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 16:4094-4104
37. Yeh YT, Ou-Yang F, Chen IF, Yang SF, Wang YY, Chuang HY, Su JH, Hou MF, Yuan SS (2006) STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma. Int J Cancer 118:2943-2947
38. Fernandes A, Hamburger AW, Gerwin BI (1999) ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer 83:564-570 (Pubitemid 29489874)
39. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP, Jove R (1997) Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8:1267-1276 (Pubitemid 28008723)
40. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TP, Lam W, Pugh T, Marra M, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE (2007) Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9:R61 (Pubitemid 350187482)
41. Eisenkraft BL, Nanus DM, Albino AP, Pfeffer LM (1991) Alpha-interferon down-regulates epidermal growth factor receptors on renal carcinoma cells: relation to cellular responsiveness to the antiproliferative action of alpha-interferon. Cancer Res 51:5881-5887
42. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB (2010) Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 16:2550-2561
43. Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW (2012) YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst 104:133-146
44. Sakaguchi S (2011) Regulatory T cells: history and perspective. Methods Mol Biol 707:3-17
45. Ochs HD, Gambineri E, Torgerson TR (2007) IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 38:112-121 (Pubitemid 47574902)
46. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8-27 (Pubitemid 44116697)